News

Harbin Gloria Pharmaceuticals (Gloria) will design and conduct the trial under the terms of its exclusive license, development, commercialization and supply agreement with Sucampo for Amitiza in China.

The new facility, located near the company’s existing Suzhou site, will help increase production capacity to meet growing demand for Pfizer Consumer Healthcare’s brands in China and the

NTRA-9620 is intended to improve post-resection bowel adaptation as well as patient outcomes, which includes reducing reliance on parenteral nutrition support and increasing enteral nutrition intake. The company

The Phase III trial is planned to be conducted in collaboration with the Gynecologic Oncology Group (GOG) Foundation and will be led by principal investigator from University of

As part of the deal, KODE would secure up to $31m in development and sales milestones, plus royalties on net sales, while Agalimmune will have exclusive rights to

Reslizumab is the company’s investigational humanized monoclonal antibody (mAb), which targets interleukin-5 (IL-5), and is being reviewed as a potential treatment for patients with eosinophilic asthma, despite an

Olipudase alfa is being evaluated to treat nonneurological manifestations of ASMD, also known as Niemann-Pick disease type B, as opposed to type A, which is characterized by neurological

As recently reported at the American Society of Clinical Oncology (ASCO) annual meeting, results show a significant reduction in the Total Symptom Score (TSS) (the proportion of patients

The study, entitled "Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion" authored by Andreas Müssigbrodt et